Skip to main content
SpringerLink
Log in

Significance of the percentage of cholesterol efflux capacity and total cholesterol efflux capacity in patients with or without coronary artery disease

  • Original Article
  • Published:
Heart and Vessels Aims and scope Submit manuscript

Abstract

We hypothesized that cholesterol efflux capacity is more useful than the lipid profile as a marker of the presence and the severity of coronary artery disease (CAD). Therefore, we investigated the associations between the presence and the severity of CAD and both the percentage of cholesterol efflux capacity and total cholesterol efflux capacity and the lipid profile including the high-density lipoprotein cholesterol (HDL-C) level in patients who underwent coronary computed tomography angiography (CTA). The subjects consisted of 204 patients who were clinically suspected to have CAD and underwent CTA. We isolated HDL from plasma by ultracentrifugation and measured the percentage of cholesterol efflux capacity using 3H-cholesterol-labeled J774 macrophage cells and calculated total cholesterol efflux capacity as follows: the percentage of cholesterol efflux capacity/100× HDL-C levels. While the percentage of cholesterol efflux capacity was not associated with the presence or the severity of CAD, total cholesterol efflux capacity and HDL-C in patients with CAD were significantly lower than those in patients without CAD. In addition, total cholesterol efflux capacity and HDL-C, but not the percentage of cholesterol efflux capacity, significantly decreased as the number of coronary arteries with significant stenosis increased. Total cholesterol efflux capacity was positively correlated with HDL-C, whereas the percentage of cholesterol efflux capacity showed only weak association. In a logistic regression analysis, the presence of CAD was independently associated with total cholesterol efflux capacity, in addition to age and gender. Finally, a receiver-operating characteristic curve analysis indicated that the areas under the curves for total cholesterol efflux capacity and HDL-C were similar. In conclusion, the percentage of cholesterol efflux capacity using the fixed amount of isolated HDL was not associated with CAD. On the other hand, the calculated total cholesterol efflux capacity that was dependent of HDL-C levels had a significant correlation with the presence of CAD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Gordon DJ, Rifkind BM (1989) High-density lipoprotein—the clinical implications of recent studies. N Engl J Med 321:1311–1316

    Article  CAS  PubMed  Google Scholar 

  2. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC, Treating to New Targets Investigators (2007) HDL cholesterol very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357:1301–1310

    Article  CAS  PubMed  Google Scholar 

  3. Ogita M, Miyauchi K, Miyazaki T, Naito R, Konishi H, Tsuboi S, Dohi T, Kasai T, Yokoyama T, Okazaki S, Kurata T, Daida H (2014) Low high-density lipoprotein cholesterol is a residual risk factor associated with long-term clinical outcomes in diabetic patients with stable coronary artery disease who achieve optimal control of low-density lipoprotein cholesterol. Heart Vessels 29:35–41

    Article  PubMed  Google Scholar 

  4. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR (1977) High density lipoprotein as a protective factor against coronary heart disease. The framingham study. Am J Med 62:707–714

    Article  CAS  PubMed  Google Scholar 

  5. AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W (2011) Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365:2255–2267 (Erratum, N Engl J Med 2012;367:189)

  6. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B, Investigators ILLUMINATE (2007) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357:2109–2122

    Article  CAS  PubMed  Google Scholar 

  7. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS, dal-OUTCOMES Investigators (2012) Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367:2089–2099

    Article  CAS  PubMed  Google Scholar 

  8. Farbstein D, Levy AP (2012) HDL dysfunction in diabetes: causes and possible treatments. Expert Rev Cardiovasc Ther 10:353–361

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ (2011) Cholesterol efflux capacity, highdensity lipoprotein function, and atherosclerosis. N Engl J Med 364:127–135

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Li XM, Tang WH, Mosior MK, Huang Y, Wu Y, Matter W, Gao V, Schmitt D, Didonato JA, Fisher EA, Smith JD, Hazen SL (2013) Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol 33:1696–1705

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Agarwala AP, Rodrigues A, Risman M, McCoy M, Trindade K, Qu L, Cuchel M, Billheimer J, Rader DJ (2015) High-density lipoprotein (HDL) phospholipid content and cholesterol efflux capacity are reduced in patients with very high HDL cholesterol and coronary disease. Arterioscler Thromb Vasc Biol 35:1515–1519

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, Neeland IJ, Yuhanna IS, Rader DR, de Lemos JA, Shaul PW (2014) HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 371:2383–2393

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Imaizumi S, Miura SI, Takata K, Takamiya Y, Kuwano T, Sugihara M, Ike A, Iwata A, Nishikawa H, Saku K (2015) Association between cholesterol efflux capacity and coronary restenosis after successful stent implantation. Heart Vessels. doi:10.1007/s00380-015-0738-1

    Google Scholar 

  14. Annema W, Dikkers A, Freark de Boer J, Dullaart RP, Sanders JS, Bakker SJ, Tietge UJ (2016) HDL cholesterol efflux predicts graft failure in renal transplant recipients. J Am Soc Nephrol 27:595–603

    Article  PubMed  Google Scholar 

  15. Singh N, Jacobs F, Rader DJ, Vanhaecke J, Van Cleemput J, De Geest B (2014) Impaired cholesterol efflux capacity and vasculoprotective function of high-density lipoprotein in heart transplant recipients. J Heart Lung Transplant 33:499–506

    Article  PubMed  Google Scholar 

  16. Mitsutake R, Niimura H, Miura S, Zhang B, Iwata A, Nishikawa H, Kawamura A, Kumagai K, Shirai K, Matsunaga A, Saku K (2006) Clinical significance of the coronary calcification score by multidetector row computed tomography for the evaluation of coronary stenosis in Japanese patients. Circ J 70:1122–1127

    Article  PubMed  Google Scholar 

  17. Dodge JT Jr, Brown BG, Bolson EL, Dodge HT (1988) Intrathoracic spatial location of coronary segments on the normal human heart. Circulation 78:1167–1180

    Article  PubMed  Google Scholar 

  18. Koyoshi R, Miura S, Kumagai N, Shiga Y, Mitsutake R, Saku K (2012) Clinical significance of flow-mediated dilation, brachial intima-media thickness and pulse wave velocity in patients with and without coronary artery disease. Circ J 76:1469–1475

    Article  PubMed  Google Scholar 

  19. Rothblat GH, de la Llera-Moya M, Atger V, Kellner-Weibel G, Williams DL, Phillips MC (1999) Cell cholesterol efflux: integration of old and new observations provides new insights. J Lipid Res 40:781–796

    CAS  PubMed  Google Scholar 

  20. Takata K, Imaizumi S, Kawachi E, Suematsu Y, Shimizu T, Abe S, Matsuo Y, Tsukahara H, Noda K, Yahiro E, Zhang B, Uehara Y, Miura S, Saku K (2014) Impact of cigarette smoking cessation on high-density lipoprotein functionality. Circ J 78:2955–2962

    Article  PubMed  Google Scholar 

  21. Ha JS, Ha CE, Chao JT, Petersen CE, Theriault A, Bhagavan NV (2003) Human serum albumin and its structural variants mediate cholesterol efflux from cultured endothelial cells. Biochim Biophys Acta 1640:119–128

    Article  CAS  PubMed  Google Scholar 

  22. Toth PP (2005) High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies. Am J Cardiol 96:50K–58K

    Article  CAS  PubMed  Google Scholar 

  23. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 106:3143–3421

    Google Scholar 

  24. Fournier N, de la Llera Moya M, Burkey BF, Swaney JB, Paterniti J Jr, Moatti N, Atger V, Rothblat GH (1996) The role of HDL phospholipids in efflux of cell cholesterol to whole serum: studies with human apoA-I transgenic rats. J Lipid Res 37:1704–1711

    CAS  PubMed  Google Scholar 

  25. Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T, Daida H, Matsuzaki M (2009) Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 54:293–302

    Article  PubMed  Google Scholar 

  26. Schoenhagen P, Tuzcu EM, Apperson-Hansen C, Wang C, Wolski K, Lin S, Sipahi I, Nicholls SJ, Magyar WA, Loyd A, Churchill T, Crowe T, Nissen SE (2006) Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the reversal of atherosclerosis with aggressive lipid lowering therapy (reversal) trial. Circulation 113:2826–2834

    Article  CAS  PubMed  Google Scholar 

  27. Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Raichlen JS, Uno K, Borgman M, Wolski K, Nissen SE (2011) Effect of two intensive statin regimens on progression of coronary disease. New Engl J Med 365:2078–2087

    Article  CAS  PubMed  Google Scholar 

  28. Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubinstein JJ, Schaefer EJ (2002) Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis 164:361–369

    Article  CAS  PubMed  Google Scholar 

  29. Shimizu T, Miura S, Tanigawa H, Kuwano T, Zhang B, Uehara Y, Saku K (2014) Rosuvastatin activates ATP-binding cassette transporter A1-dependent efflux ex vivo and promotes reverse cholesterol transport in macrophage cells in mice fed a high-fat diet. Arterioscler Thromb Vasc Biol 34:2246–2253

    Article  CAS  PubMed  Google Scholar 

  30. Triolo M, Annema W, de Boer JF, Tietge UJ, Dullaart RP (2014) Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes. Eur J Clin Invest 44:240–248

    Article  CAS  PubMed  Google Scholar 

  31. Fine JJ, Hopkins CB, Ruff N, Newton FC (2006) Comparison of accuracy of 64-slice cardiovascular computed tomography with coronary angiography in patients with suspected coronary artery disease. Am J Cardiol 97:173–174

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Mses. Sayo Tomita, Satomi Abe and Yoshino Matsuo for their assistance.

Author information

Author notes

    Authors and Affiliations

    1. Department of Cardiology, Fukuoka University School of Medicine, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan

      Kenji Norimatsu, Takashi Kuwano, Shin-ichiro Miura, Tomohiko Shimizu, Yuhei Shiga, Yasunori Suematsu, Yuiko Miyase, Sen Adachi, Ayumi Nakamura, Satoshi Imaizumi, Atsushi Iwata, Hiroaki Nishikawa, Yoshinari Uehara & Keijiro Saku

    2. Department of Molecular Cardiovascular Therapeutics, Fukuoka University School of Medicine, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan

      Shin-ichiro Miura, Yoshinari Uehara & Keijiro Saku

    Authors
    1. Kenji Norimatsu
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Takashi Kuwano
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Shin-ichiro Miura
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Tomohiko Shimizu
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Yuhei Shiga
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Yasunori Suematsu
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Yuiko Miyase
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Sen Adachi
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. Ayumi Nakamura
      View author publications

      You can also search for this author in PubMed Google Scholar

    10. Satoshi Imaizumi
      View author publications

      You can also search for this author in PubMed Google Scholar

    11. Atsushi Iwata
      View author publications

      You can also search for this author in PubMed Google Scholar

    12. Hiroaki Nishikawa
      View author publications

      You can also search for this author in PubMed Google Scholar

    13. Yoshinari Uehara
      View author publications

      You can also search for this author in PubMed Google Scholar

    14. Keijiro Saku
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Shin-ichiro Miura.

    Ethics declarations

    Conflict of interest

    K S. is a Chief Director and S. M. is a Director of NPO Clinical and Applied Science, Fukuoka, Japan. K. S. has an Endowed “Department of Molecular Cardiovascular Therapeutics” supported by MSD, Co. LTD. S. M. and Y. U. belong to the Department of Molecular Cardiovascular Therapeutics, which is supported by MSD, Co. LTD.

    Additional information

    K. Norimatsu and T. Kuwano contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Norimatsu, K., Kuwano, T., Miura, Si. et al. Significance of the percentage of cholesterol efflux capacity and total cholesterol efflux capacity in patients with or without coronary artery disease. Heart Vessels 32, 30–38 (2017). https://doi.org/10.1007/s00380-016-0837-7

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s00380-016-0837-7

    Keywords

    Search

    Navigation